longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Apnimed

APMD

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 5.13, within the reasonable range, cheaper than 21.95% of the time in the past 1 years, and the industry ranks 7/256, the industry Median -1.39.

5.13xP/E
$21.09Stock price
$4.11Earnings per share
5.13xP/E
Stock price$21.09Earnings per share$4.11

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-34.89x
Typical range
-45.71x–5.27x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
NVOUSNovo Nordisk AS
9.48x5.88%$171.61B
SGIOYUSShionogi
9.37x--$15.78B
HYPMYUSHypera S.A.
9.97x--$3.27B
INVAUSInnoviva
4.19x32.30%$1.50B
APMDUSApnimed
5.13x114.94%$839.87M
CRMDUSCormedix
3.29x75.74%$611.86M
ORMPUSOramed Pharma
1.13x198.00%$196.76M
OGIUSOrganigram
2.39x510.33%$148.51M
SDEVUSStablecoin Development
0.16x--$75.42M
BTMDUSbiote Corp.
7.48x127.70%$43.83M
OWPCUSOne World Products, Inc.
0.04x--$142.42K

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.